Over 3 million parents across the world have already trusted MiYOSMART.1 Will you?

Evidence you can trust.

Boy and girl playing outside wearing HOYA MiYOSMART sunglasses

Clinical studies are the foundation of any evidence-based treatment.

 They aim to:

  • Evaluate effectiveness of a treatment
  • Evaluate safety of a treatment
  • Provide answers to topics of interest regarding a specific treatment

This information can help you assess if a treatment is the right solution for your child with an Eye Care Professional.

We carried out over 90 scientific studies that provide high-quality evidence, to give you the confidence when considering MiYOSMART as a treatment solution for your child’s myopia.

HOYA MiYOSMART graphic with globe and glasses

Eyeglass lenses that really work

  • A 2-year clinical study in Hong Kong showed that myopia progression slowed down on average by 60% in children that used MiYOSMART lenses, compared with regular single-vision lenses.2 Similar results were seen in a UK-based clinical study.3
  • Additionally, in the Hong Kong study, 1 in 5 children who wore MiYOSMART lenses had no myopia progression at all in the first 2 years.2
HOYA MiYOSMART graphic with globe and glasses

Suitable for most children

We’ve conducted multiple clinical studies in different age groups and parts of the world,25 so MiYOSMART spectacle lenses deliver effective myopia management for children of various ethnic backgrounds.5

Based on a solid scientific theory 

The DIMS Technology used in MiYOSMART lenses is based on a well-established and widely accepted scientific theory.6.7

Long-term wear benefits

8-year follow-up study revealed that the myopia management effect was sustained in those children who wore MiYOSMART spectacle lenses for up to 6 and 8 years respectively,8,9 suggesting that there is benefit in wearing the spectacle lenses long-term to improve myopia management outcomes.9

 

Same as comment on other webpage, we would recommend keeping 2 as you be left with a webpage with one efficacy claim that is unpublished

 

Well tolerated with no long-term adverse events

  • MiYOSMART spectacle lenses are generally well tolerated among children3,10
  • They are a non-invasive solution, unlike other treatments out there (like atropine or Ortho-K), and it usually only takes children a few days to adapt to their new MiYOSMART spectacle lenses
  • A 6-year clinical study in Hong Kong showed no long-term side effects from wearing MiYOSMART spectacle lenses
  • No long-term safety concerns were identified over the 8 years follow-up period9
Girl playing outside wearing glasses with HOYA MiYOSMART lenses

Safe on the road

MiYOSMART lenses don’t cause glare sensitivity or worsen contrast vision so they don’t impair vision in traffic, neither alone nor with low-dose atropine eye drops.10 This means that after a 2-week adaptation period, your child can navigate traffic without distracting glare from traffic lights or other vision disturbances.

 

Compatible with atropine eye drops

MiYOSMART lenses work in synergy with low-dose atropine eye drops. In fact, recent clinical studies from Europe4 and China12 found that the combination treatment of MiYOSMART lenses and low-dose atropine eye drops was more effective, than MiYOSMART or atropine alone.

In fact, a study run in Spain shows that atropine eye drops may enhance the effect of MiYOSMART spectacle lenses on slowing myopia progression.13

However, this is a treatment decision that should be made under the supervision of an Eye Care Professional.

Children with myopia glasses skipping outside

No 're-bound' effect

If your child stops their treatment with MiYOSMART lenses, myopia will not ‘re-bound’ to what it was before treatment.7 This is unlike other popular treatment methods, like high-dose atropine eye drops or orthokeratology.12, 13

Children with myopia glasses skipping outside

No impact to your child’s lifestyle

MiYOSMART spectacle lenses will enable your child to spend active time outdoors. Neither the lenses, nor the treatment will have an impact on their favourite activities such as team sports with their friends.16

Overall, parents and children should not be concerned over the impact of MiYOSMART spectacle lenses on vision-related quality of life as wearing MiYOSMART is comparable to single vision spectacle lenses.17

Disclaimers

MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

MiYOSMART spectacle lenses may not be able to address individuals’ conditions due to natural deficiencies, illness, pre-existing medical conditions and/or advanced age of consumers. The information contained herein is for general information and is not intended to constitute medical advice. Please consult your Eye Care Professional for more information prior to the use of MiYOSMART spectacle lenses.

References

  • 1. Based on the number of MiYOSMART spectacle lenses sold according to HOYA’s sales data on file as of April 25.
  • 2. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8. DOI: 10.1136/bjophthalmol-2018-313739.
  • 3. McCullough S, Barr H, Fulton J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). Invest Ophthalmol Vis Sci. 2023;64(8):4945.
  • 4. Nucci P, Lembo A, Schiavetti I, et al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023;18(2):e0281816. DOI: 10.1371/journal.pone.0281816.
  • 5. Saunders K.J. et al.  Multi-Site Observational Study of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: 2-year results. EAOO 2025 Paper Presentation. https://www.hoyavision.com/visionary-knowlegde/conference-EAOO-2025/ [Accessed May 2025]
  • 6. Troilo D, Smith EL, 3rd, Nickla DL, et al. IMI - Report on Experimental Models of Emmetropization and Myopia. Invest Ophthalmol Vis Sci. 2019;60(3):M31-M88. DOI: 10.1167/iovs.18-25967.
  • 7. Nemeth J, Tapaszto B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853-83. DOI: 10.1177/1120672121998960.
  • 8. Lam CSY, Tang WC, Zhang HY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13(1):5475. DOI: 10.1038/s41598-023-32700-7.
  • 9. Leung et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Abstract presented at ARVO. Available at: https://www.hoyavision.com/globalassets/__regional-assets/global/arvo-2025/leung-et-al.-dims-8y-study-arvo-2025-abstract.pdf (Accessed May 2025)
  • 10. Lu Y, Lin Z, Wen L, et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol. 2020;211:207-16. DOI: 10.1016/j.ajo.2019.12.002.
  • 11. Kaymak H, Mattern AI, Graff B, et al. Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression. Klin Monbl Augenheilkd. 2022;239(10):1197-205. DOI: 10.1055/a-1930-7116.
  • 12. Huang Z, Chen XF, He T, et al. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12(1):22311. DOI: 10.1038/s41598-022-25599-z.
  • 13. Guemes-Villahoz N, Talavero González P, Porras-Ángel P, et al Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Br J Ophthalmol. 2025; May 09:doi: 10.1136/bjo-2024-326852 (Epub ahead of print).
  • 14. Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye. 2017;40(2):82-7. DOI: 10.1016/j.clae.2016.12.002.
  • 15. Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116(3):572-9. DOI: 10.1016/j.ophtha.2008.10.020.
  • 16. Fatimah M, Agarkar S, Narayanan A. Impact of defocus incorporated multiple segments (DIMS) spectacle lenses for myopia control on quality of life of the children: a qualitative study. BMJ Open Ophthalmol. 2024 Jul 2;9(1):e001562. doi: 10.1136/bmjophth-2023-001562. PMID: 38960416; PMCID: PMC11227816.
  • 17. Li X, Ma W, Song Y, Yap M, Liu L. Comparison of Myopic Progression and Quality of Life Wearing Either DIMs Lenses or Single-Vision Myopia Correcting Spectacles. J Ophthalmol. 2025 Feb 12;2025:9959251. doi: 10.1155/joph/9959251. PMID: 39974171; PMCID: PMC11839264.